Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy

Ortenzi, Andrea and Paggi, Aldo and Foschi, Nicoletta and Sabbatini, Deborah and Pistoli, Emore (2008) Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy. Functional Neurology; New Trends in Interventional Neurosciences, 23 (2). pp. 97-100. ISSN 1971-3274

[img] PDF
portiere.pdf - Published Version
Restricted to Repository staff only

Download (72kB)
Official URL: http://www.functionalneurology.it

Abstract

The aim of this study was to investigate the relationships between oxcarbazepine (OXC) dosage, metabolite mono-hydroxy-derivative (MHD) serum concentrations, number of concomitant antiepileptic drugs, age and incidence of adverse events (AEs) in epileptic patients. A retrospective analysis was conducted of 414 consecutive epileptic patients on OXC alone or added-on to previous therapy. The sample was collected from the period 2001 to 2006. Statistical analysis was performed in two groups: with and without AEs. Eighty-seven patients (21%) experienced at least one AE. The most frequent was hyponatremia, reported in 9.2%. OXC was discontinued because of AEs in 27 cases. There were no important differences between patients with and without AEs, except for age (p=0.04). The categorization of patients into three different age ranges, <20, 20-59 and Ž60 years, disclosed that the risk of AEs is notably lower in young (<20 years) and adult (20-59 years) patients (OR 0.46 and 0.51, respectively). In particular, the patients who experienced hyponatremia were significantly older than those who did not (p=0.0045). The other variables showed no major changes according to age. The incidence of major AEs during OXC treatment, leading to withdrawal, was found to be low and influenced by age, but not by OXC dosage, MHD concentrations or number of concomitant antiepileptic drugs

Item Type: Article
Uncontrolled Keywords: Adverse events, epilepsy, mono-hydroxy-derivative, oxcarbazepine
Subjects: 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 615 Farmacologia e terapeutica
600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 615 Farmacologia e terapeutica > 615.2 Farmaci inorganici
600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) > 616.8 Malattie del sistema nervoso e disturbi mentali (Classificare qui la Neuropsichiatria, la Neurologia) > 616.85 Malattie varie del sistema nervoso e disturbi mentali di diverso genere > 616.853 Epilessia
Depositing User: Danilo Dezzi
Date Deposited: 18 Jul 2012 11:43
Last Modified: 18 Jul 2012 11:43
URI: http://eprints.bice.rm.cnr.it/id/eprint/3685

Actions (login required)

View Item View Item